#United States #Tucson #Accuray #CyberKnife #CNS Tumors

Accuray CyberKnife® Platform Advancements in CNS Tumors

Accuray Incorporated, a leading innovator in the field of radiation therapy, recently presented groundbreaking findings at the 2025 Radiosurgery Society Scientific Meeting held in Tucson, Arizona. The studies emphasize the capabilities of the CyberKnife® System in treating central nervous system (CNS) tumors, a category notorious for their severity and high fatality rates.

The Efficacy of CyberKnife System

The data showcased revealed that the CyberKnife System is designed to deliver stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) with unparalleled precision. These advanced non-surgical methods allow for treatment in as few as one to five sessions, targeting tumors with incredible accuracy. The CyberKnife employs sophisticated image guidance and features up to 1,000 beam angles to adjust its delivery in real-time, enabling it to accommodate any movement by the patient or tumor.

Long-Term Data Highlights

One of the compelling studies presented included 25-year data on the treatment of vestibular schwannoma (VS) with the CyberKnife System. This common but non-cancerous tumor can lead to significant issues such as hearing loss and vertigo. Remarkably, the long-term efficacy of CyberKnife in managing VS demonstrated a local control rate of 89.3% and an overall survival rate of 97.1% at the 25-year mark. This remarkable data underscores the system's potential to deliver sustained local control and improve patients' quality of life significantly.

Innovation in Treating Complex Conditions

In addition to its success with VS, the CyberKnife System was evaluated in the treatment of spinal metastases, a challenging condition where cancer spreads to the spinal column. The innovative donut-shaped circumferential SBRT technique aims to deliver high doses of radiation to tumors while safeguarding the sensitive spinal cord from potential radiation damage. The research confirmed the safety and effectiveness of the CyberKnife for spinal metastases, providing high local tumor control rates with minimal complications.

Expanding Options for Painful Neurological Conditions

Furthermore, studies on trigeminal neuralgia—the notorious condition causing severe facial pain—indicated successful outcomes with the CyberKnife. Among elderly patients treated, 90% experienced significant pain relief, proving to be a crucial option for those whose health conditions restrict them from undergoing surgery. Similarly, treatment for occipital condyle metastasis yielded a 93.8% local control rate, with 87.5% of patients reporting relief from pain.

A Step Forward in Radiation Therapy

The insights from these studies reflect Accuray's commitment to providing innovative, market-altering solutions in radiation therapy. With a focus on continuous improvement, the CyberKnife System stands at the forefront of expanding care options for patients facing previously limited choices. The technology not only enhances treatment quality but also serves to improve patient outcomes and longevity.

Accuray's headquarters in Madison, Wisconsin, drives the company’s mission to revolutionize the treatment landscape through advanced technology and patient-centered care. By actively collaborating with healthcare professionals, they aspire to facilitate quicker recovery times and better quality of life for patients undergoing treatment.

For more information on Accuray and its target-driven approach to improving cancer treatment, visit www.accuray.com.